These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 29369974)

  • 1. Therapeutic Drug Monitoring of Second-Generation Antipsychotics for the Estimation of Early Drug Effect in First-Episode Psychosis: A Cross-sectional Assessment.
    Bustillo M; Zabala A; Querejeta I; Carton JI; Mentxaka O; González-Pinto A; García S; Meana JJ; Eguiluz JI; Segarra R
    Ther Drug Monit; 2018 Apr; 40(2):257-267. PubMed ID: 29369974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Pilot Study of the Usefulness of a Single Olanzapine Plasma Concentration as an Indicator of Early Drug Effect in a Small Sample of First-Episode Psychosis Patients.
    Zabala A; Bustillo M; Querejeta I; Alonso M; Mentxaka O; González-Pinto A; Ugarte A; Meana JJ; Gutiérrez M; Segarra R
    J Clin Psychopharmacol; 2017 Oct; 37(5):569-577. PubMed ID: 28796022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics.
    Spina E; Hiemke C; de Leon J
    Expert Opin Drug Metab Toxicol; 2016; 12(4):407-22. PubMed ID: 26878495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons.
    Haddad PM; Das A; Keyhani S; Chaudhry IB
    J Psychopharmacol; 2012 May; 26(5 Suppl):15-26. PubMed ID: 22057019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach.
    Castro-Fornieles J; Parellada M; Soutullo CA; Baeza I; Gonzalez-Pinto A; Graell M; Paya B; Moreno D; de la Serna E; Arango C
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):327-36. PubMed ID: 18759642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychiatrists' perspectives on antipsychotic dose and the role of plasma concentration therapeutic drug monitoring.
    Best-Shaw L; Gudbrandsen M; Nagar J; Rose D; David AS; Patel MX
    Ther Drug Monit; 2014 Aug; 36(4):486-93. PubMed ID: 24384695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twenty-four months of antipsychotic treatment in children and adolescents with first psychotic episode: discontinuation and tolerability.
    Noguera A; Ballesta P; Baeza I; Arango C; de la Serna E; González-Pinto A; Parellada M; Graell M; Moreno C; Otero S; Castro-Fornieles J
    J Clin Psychopharmacol; 2013 Aug; 33(4):463-71. PubMed ID: 23771198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship Between Daily Dose, Serum Concentration, and Clinical Response to Quetiapine in Children and Adolescents with Psychotic and Mood Disorders.
    Albantakis L; Egberts K; Burger R; Kulpok C; Mehler-Wex C; Taurines R; Unterecker S; Wewetzer C; Romanos M; Gerlach M
    Pharmacopsychiatry; 2017 Nov; 50(6):248-255. PubMed ID: 28561203
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinically significant drug interactions with atypical antipsychotics.
    Kennedy WK; Jann MW; Kutscher EC
    CNS Drugs; 2013 Dec; 27(12):1021-48. PubMed ID: 24170642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Drug Monitoring in Children and Adolescents Under Pharmacotherapy With Olanzapine in Daily Clinical Practice.
    Fekete S; Wewetzer C; Mehler-Wex C; Holtkamp K; Burger R; Reichert S; Taurines R; Romanos M; Gerlach M; Egberts K
    Ther Drug Monit; 2017 Jun; 39(3):273-281. PubMed ID: 28383317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosing quetiapine in drug-naive first-episode psychosis: a controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years.
    Berger GE; Proffitt TM; McConchie M; Kerr M; Markulev C; Yuen HP; O'Donnell C; Lubman D; Polari A; Wood S; Amminger PG; McGorry PD
    J Clin Psychiatry; 2008 Nov; 69(11):1702-14. PubMed ID: 19036233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.
    Fraguas D; Correll CU; Merchán-Naranjo J; Rapado-Castro M; Parellada M; Moreno C; Arango C
    Eur Neuropsychopharmacol; 2011 Aug; 21(8):621-45. PubMed ID: 20702068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effectiveness and tolerability of aripiprazole as initial choice of treatment in first episode psychosis in an early intervention service: A one-year outcome study.
    Malla A; Mustafa S; Rho A; Abadi S; Lepage M; Joober R
    Schizophr Res; 2016 Jul; 174(1-3):120-125. PubMed ID: 27157800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stability of medication in early psychosis: a comparison between second-generation and low-dose first-generation antipsychotics.
    Opjordsmoen S; Melle I; Friis S; Haahr U; Johannessen JO; Larsen TK; Rund BR; Simonsen E; Vaglum P; McGlashan TH
    Early Interv Psychiatry; 2009 Feb; 3(1):58-65. PubMed ID: 21352176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Side effect burden of antipsychotic drugs in real life - Impact of gender and polypharmacy.
    Iversen TSJ; Steen NE; Dieset I; Hope S; Mørch R; Gardsjord ES; Jørgensen KN; Melle I; Andreassen OA; Molden E; Jönsson EG
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Mar; 82():263-271. PubMed ID: 29122637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aripiprazole for drug-naive or antipsychotic-short-exposure subjects with ultra-high risk state and first-episode psychosis: an open-label study.
    Liu CC; Chien YL; Hsieh MH; Hwang TJ; Hwu HG; Liu CM
    J Clin Psychopharmacol; 2013 Feb; 33(1):18-23. PubMed ID: 23277261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early intervention with second-generation antipsychotics in first-episode psychosis: results of an 8-week naturalistic study.
    Josiassen RC; Shaughnessy RA; Filymer DM; Donohue AM; Kacso M; Finkel N; Curtis J; Audino B; Skuban N
    Early Interv Psychiatry; 2010 Feb; 4(1):57-63. PubMed ID: 20199481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.